144 related articles for article (PubMed ID: 26377323)
1. EZH2 is a sensitive marker of malignancy in salivary gland tumors.
Hajósi-Kalcakosz S; Vincze E; Dezső K; Paku S; Rókusz A; Sápi Z; Tóth E; Nagy P
Diagn Pathol; 2015 Sep; 10():163. PubMed ID: 26377323
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors.
Hajósi-Kalcakosz S; Dezső K; Bugyik E; Bödör C; Paku S; Pávai Z; Halász J; Schlachter K; Schaff Z; Nagy P
Diagn Pathol; 2012 Jul; 7():86. PubMed ID: 22809481
[TBL] [Abstract][Full Text] [Related]
3. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.
Vékony H; Raaphorst FM; Otte AP; van Lohuizen M; Leemans CR; van der Waal I; Bloemena E
J Clin Pathol; 2008 Jun; 61(6):744-9. PubMed ID: 18326020
[TBL] [Abstract][Full Text] [Related]
4. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
6. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.
Wan L; Li X; Shen H; Bai X
Clin Transl Oncol; 2013 Feb; 15(2):132-8. PubMed ID: 22855181
[TBL] [Abstract][Full Text] [Related]
8. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
9. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor.
Kampilafkos P; Melachrinou M; Kefalopoulou Z; Lakoumentas J; Sotiropoulou-Bonikou G
Am J Dermatopathol; 2015 Feb; 37(2):138-44. PubMed ID: 25614949
[TBL] [Abstract][Full Text] [Related]
12. Thyroid-1 transcription factor expression in salivary gland tumors.
Brod JMM; Lourenção P; Pereira FP; Barreto IS; Garcia Rosa AC; Sperandio M; Araújo VC; Soares AB
Pathol Res Pract; 2019 Oct; 215(10):152610. PubMed ID: 31477325
[No Abstract] [Full Text] [Related]
13. Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.
Hayashi A; Morikawa T; Kawai T; Kume H; Ishikawa S; Homma Y; Fukayama M
Virchows Arch; 2014 Apr; 464(4):463-71. PubMed ID: 24446035
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of enhancer of Zeste Homolog 2 (EZH2) differentiates squamous cell carcinoma from normal skin and actinic keratosis.
Xie Q; Wang H; Heilman ER; Walsh MG; Haseeb MA; Gupta R
Eur J Dermatol; 2014; 24(1):41-5. PubMed ID: 24413452
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Detection of Proliferative Marker Ki-67 in Benign and Malignant Salivary Gland Tumors.
Bussari S; Ganvir SM; Sarode M; Jeergal PA; Deshmukh A; Srivastava H
J Contemp Dent Pract; 2018 Apr; 19(4):375-383. PubMed ID: 29728539
[No Abstract] [Full Text] [Related]
17. BSND is a Novel Immunohistochemical Marker for Oncocytic Salivary Gland Tumors.
Shinmura K; Kato H; Kawanishi Y; Kamo T; Inoue Y; Yoshimura K; Sugiyama K; Misawa K; Hosokawa S; Mineta H; Sugimura H
Pathol Oncol Res; 2018 Apr; 24(2):439-444. PubMed ID: 28470573
[TBL] [Abstract][Full Text] [Related]
18. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
Panousis D; Xepapadakis G; Lagoudianakis E; Karavitis G; Salemis N; Koronakis N; Patsouris E; Koronarchis D; Grosomanidis D; Chryssikos G; Ntasiou P; Kyriakidou V; Athanassiadou AM; Athanassiadou P
J BUON; 2013; 18(4):879-85. PubMed ID: 24344012
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors.
Rössle M; Cathomas G; Bonapace L; Sachs M; Dehler S; Storz M; Huber G; Moch H; Junt T; Mertz KD
Int J Surg Pathol; 2016 Aug; 24(5):394-400. PubMed ID: 26912475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
